Global Blood Therapeutics (GBT) Reaches Agreement with FDA on Design of Phase 3 GBT440 Trial in SCD
- Wall Street set to open flat as investors test rally
- Western Digital (WDC) Raises Q2 Outlook
- Biotech, Pharma Stocks Weaker Amid Trump Comments on Lower Drug Prices
- Oil slips on doubts output cut will end global glut
- Pre-Open Stock Movers 12/07: (EMKR) (PLAY) (WDC) Higher; (SIGM) (AVAV) (BLUE) Lower (more...)
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet need, today announced that it has reached agreement with the U. S. Food and Drug Administration (FDA) regarding the design of its pivotal trial for GBT440 in adults and adolescents with sickle cell disease (SCD).
The Phase 3 HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization) Study will be conducted at leading SCD sites globally and will enroll adults and adolescents with SCD who have had at least one episode of vaso-occlusive crisis (VOC) in the previous year. The HOPE Study is expected to begin screening patients by December with top-line data anticipated in the first half of 2019.
“We are extremely pleased with our interactions and outcome of our pre-Phase 3 process with the FDA. We believe that this agreed-upon study design underscores our common goal to address the urgent unmet medical need for new disease-modifying preventative therapies for SCD and the importance of innovative regulatory strategies to bring new therapies to market to treat these patients,” said Ted W. Love, M.D., president and chief executive officer of GBT. “Solidification of the path forward for our pivotal study is an important milestone and we believe the HOPE Study design has a strong grounding in GBT440’s mechanism of action, including its potential to fundamentally modify the course of the disease by inhibiting sickle hemoglobin polymerization.”
HOPE Study DesignThe HOPE Study is a randomized, double-blind, placebo-controlled, multi-national, Phase 3 trial, which will enroll up to 400 patients age 12 and older with SCD who have had at least one episode of vaso-occlusive crisis (VOC) in the previous year.
The HOPE Study will be conducted in two-parts:
Part A - Compare two dose levels of GBT440 – 900 mg and 1500 mg versus placebo. Part A will include up to 150 patients.
Part B - To include 250 patients randomized to placebo or a dose of GBT440 based on Part A.
The main objectives of Part A are to select the optimal dose, define the final secondary endpoints for Part B and qualify the Patient Reported Outcome (PRO) instrument.
The primary efficacy endpoint of the HOPE Study will be the proportion of patients who achieve a >1 g/dL increase in hemoglobin at 24 weeks of treatment vs baseline. Our discussions with the FDA have focused on a pathway to full approval based on the HOPE Study, by meeting the primary and at least one key secondary endpoint.
Key secondary efficacy endpoints will include the effect of GBT440 on SCD symptom exacerbation, which will be measured by our PRO instrument, in addition to overall SCD symptoms as compared to placebo. The PRO is administered on a hand-held electronic device, and is designed to capture the full range of daily SCD symptoms. We will also assess traditionally defined VOCs as well as hospitalizations and red blood cell transfusions as secondary endpoints.
“Previous SCD studies have generally focused on VOC, defined as a painful crisis requiring hospital or emergency room utilization. But we know that patients have 4-5 times more frequent painful crises, with or without utilization. As a result, the burden of painful crises is dramatically under-reported,” said Wally Smith, M.D., Florence Neal Cooper Smith Professor of Sickle Cell Disease Director, a comprehensive sickle cell program at Virginia Commonwealth University. “By utilizing the PRO, the innovative design of the HOPE Study should allow measurement of the true burden of SCD painful crises and other symptoms.”
Conference Call with Management Management will host a conference call to provide a program update today at 1:30 p.m. PT/ 4:30 p.m. ET. To participate in the conference call, please dial (844) 471-0808 (domestic) or (480) 696-7309 (international) and refer to conference ID 3206614. Live audio of the conference call will be simultaneously webcast and will be available under the Investors and Media section of the company’s website at www.globalbloodtx.com.
The webcast will be archived under the investors and media section of the company’s website and will be available for replay for at least one month after the conference call.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ARIAD Pharma (ARIA) Presents Strong Data from Brigatinib ALTA Trial in ALK+ NSCLC
- Starbucks Coffee (SBUX) to Present Five-Year Growth Plan at Investor Conference
- UPDATE: Linde to Resume Talks with Praxair (PX); Appoints Belloni as CEO
Create E-mail Alert Related CategoriesCorporate News, FDA, Hot Corp. News, Hot FDA News, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!